( DrugBank: - / KEGG DRUG: - )
2 diseases
56. ベーチェット病
臨床試験数 : 81 / 薬物数 : 107 - (DrugBank : 30) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 116
Showing 1 to 10 of 81 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05767047 (ClinicalTrials.gov) | March 10, 202320230310 | 8/3/202320230308 | A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psor ... | A Phase 3, Multicenter, Open-label, Long-term Extension Study of Apremilast in Children 2 Years of Age or Older With Oral Ulcers Associated With Behçet's Disease or 5 Years of Age or Older With Juvenile Psoriatic Arthritis A Phase 3, Multicenter, Open-label, Long-term Extension Study of Apremilast in Children 2 Years of A ... | Behçet's Disease;Juvenile Psoriatic Arthritis | Drug: Apremilast | Amgen | NULL | Not yet recruiting | 5 Years | 18 Years | All | 48 | Phase 3 | NULL |
| 2 | EUCTR2022-003024-41-ES (EUCTR) | 25/01/202320230125 | 25/11/202220221125 | Apremilast study in children with active oral ulcers associated with Behçet's Disease or Juvenile Psoriatic Arthritis Apremilast study in children with active oral ulcers associated with Behçet's Disease or Juvenile Ps ... | A Phase 3, Multicenter, Open-label, Long-term Extension Study of Apremilast in Children 2 Years of Age or Older With Oral Ulcers Associated With Behçet’s Disease or 5 Years of Age or Older With Juvenile Psoriatic Arthritis A Phase 3, Multicenter, Open-label, Long-term Extension Study of Apremilast in Children 2 Years of A ... | Subjects with active Behçet's Disease or Juvenile Psoriatic Arthritis <br>MedDRA version: 21.1;Level: LLT;Classification code 10004212;Term: Behcet's disease;System Organ Class: 100000004866 <br>MedDRA version: 20.0;Classification code 10079454;Term: Systemic juvenile idiopathic arthritis;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Subjects with active Behçet's Disease or Juvenile Psoriatic Arthritis <br>MedDRA version: 21.1;Level ... | Trade Name: Otezla<br>Product Name: Apremilast 20 mg<br>Product Code: AMG 407<br>INN or Proposed INN: Apremilast<br>Trade Name: Otezla<br>Product Name: Apremilast 30 mg<br>Product Code: AMG 407<br>INN or Proposed INN: Apremilast<br>Product Name: Apremilast<br>Product Code: AMG 407<br>INN or Proposed INN: Apremilast Trade Name: Otezla<br>Product Name: Apremilast 20 mg<br>Product Code: AMG 407<br>INN or Proposed INN ... | Amgen Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes<br>Male: yes | 48 | Phase 3 | France;Greece;Spain;Turkey;Israel;United Kingdom;Italy;Switzerland | ||
| 3 | NCT05683626 (ClinicalTrials.gov) | December 15, 202220221215 | 4/1/202320230104 | Safety and Efficacy of Adalimumab Therapy for Treatment of Behcet's Disease-related Uveitis in Sohag University Hospital Safety and Efficacy of Adalimumab Therapy for Treatment of Behcet's Disease-related Uveitis in Sohag ... | Safety and Efficacy of Adalimumab Therapy for Treatment of Behcet's Disease-related Uveitis in Sohag University Hospital Safety and Efficacy of Adalimumab Therapy for Treatment of Behcet's Disease-related Uveitis in Sohag ... | Uveitis | Drug: Humira | Sohag University | NULL | Recruiting | 18 Years | 40 Years | All | 40 | Egypt | |
| 4 | ChiCTR2100052808 | 2022-01-0120220101 | 2021-11-0520211105 | Mechanism of neutrophils activating cGAS-STING pathway through NETs to activate NLRP3 and promote macrophage pyrosis to promote behcet disease progression Mechanism of neutrophils activating cGAS-STING pathway through NETs to activate NLRP3 and promote ma ... | Mechanism of neutrophils activating cGAS-STING pathway through NETs to activate NLRP3 and promote macrophage pyrosis to promote behcet disease progression Mechanism of neutrophils activating cGAS-STING pathway through NETs to activate NLRP3 and promote ma ... | Behcet's disease | Control group:No;Active period Behcet's disease(BD) group:No;Remission period BD group:No; | Huadong Hospital of Fudan University | NULL | Recruiting | 18 | 55 | Both | Control group:20;Active period Behcet's disease(BD) group:20;Remission period BD group:20; | China | |
| 5 | NCT04528082 (ClinicalTrials.gov) | September 9, 202120210909 | 24/8/202020200824 | Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed by an Active Treatment Phase to Evaluate the Efficacy and Safety of Apremilast in Children From 2 to Less Than 18 Years of Age With Active Oral Ulcers Associated With Behçet's Disease (BEAN) A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed ... | Behçet Disease | Drug: Apremilast;Drug: Placebo | Amgen | NULL | Recruiting | 2 Years | 17 Years | All | 60 | Phase 3 | France;Greece;Israel;Italy;Spain;Switzerland;United Kingdom |
| 6 | EUCTR2019-002787-27-IT (EUCTR) | 24/05/202120210524 | 07/06/202120210607 | Apremilast study in children with active oral ulcers associated with Behçet's Disease | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled,Parallel Group Study, Followed by an Active Treatment Phase to Evaluate the Efficacy and Safety of Apremilast in Children From 2 to Less Than 18 Years of Age With Active Oral Ulcers Associated With Behçet's Disease (BEAN) - BEAN A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled,Parallel Group Study, Followed ... | Subjects with active Behçet's Disease <br>MedDRA version: 21.1;Level: LLT;Classification code 10004212;Term: Behcet's disease;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Subjects with active Behçet's Disease <br>MedDRA version: 21.1;Level: LLT;Classification code 100042 ... | Trade Name: OTEZLA - 10 MG + 20 MG + 30 MG COMPRESSA RIVESTITA CON FILM USO ORALE - BLISTER (PVC/ALU) IN UN ASTUCCIO - 4 COMPRESSE DA 10 MG + 4 COMPRESSE DA 20 MG +19 COMPRESSE DA 30 MG<br>Product Name: Apremilast<br>Product Code: [AMG407]<br>INN or Proposed INN: Apremilast<br>Trade Name: OTEZLA - 10 MG + 20 MG + 30 MG COMPRESSA RIVESTITA CON FILM USO ORALE - BLISTER (PVC/ALU) IN UN ASTUCCIO - 4 COMPRESSE DA 10 MG + 4 COMPRESSE DA 20 MG +19 COMPRESSE DA 30 MG<br>Product Name: Apremilast<br>Product Code: [AMG407]<br>INN or Proposed INN: Apremilast<br>Trade Name: OTEZLA - 10 MG + 20 MG + 30 MG COMPRESSA RIVESTITA CON FILM USO ORALE - BLISTER (PVC/ALU) IN UN ASTUCCIO - 4 COMPRESSE DA 10 MG + 4 COMPRESSE DA 20 MG +19 COMPRESSE DA 30 MG<br>Product Name: Apremilast<br>Product Code: [AMG 407]<br>INN or Proposed INN: Apremilast<br>Product Name: Apremilast<br>Product Code: [AMG407]<br>INN or Proposed INN: Apremilast Trade Name: OTEZLA - 10 MG + 20 MG + 30 MG COMPRESSA RIVESTITA CON FILM USO ORALE - BLISTER (PVC/ALU ... | AMGEN INC. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes<br>Male: yes | 60 | Phase 3 | France;Greece;Israel;Netherlands;Switzerland;Italy | ||
| 7 | EUCTR2019-002787-27-GR (EUCTR) | 20/05/202120210520 | 07/05/202120210507 | Apremilast study in children with active oral ulcers associated with Behçet’s Disease | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed by an Active Treatment Phase to Evaluate the Efficacy and Safety of Apremilast in Children From 2 to Less Than 18 Years of Age With Active Oral Ulcers Associated With Behçet’s Disease (BEAN) A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed ... | Subjects with active Behçet’s Disease <br>MedDRA version: 21.1;Level: LLT;Classification code 10004212;Term: Behcet's disease;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Subjects with active Behçet’s Disease <br>MedDRA version: 21.1;Level: LLT;Classification code 100042 ... | Trade Name: Otezla<br>Product Name: Apremilast 10 mg<br>Product Code: AMG-407<br>INN or Proposed INN: Apremilast<br>Trade Name: Otezla<br>Product Name: Apremilast 20 mg<br>Product Code: AMG-407<br>INN or Proposed INN: Apremilast<br>Trade Name: Otezla<br>Product Name: Apremilast 30 mg<br>Product Code: AMG-407<br>INN or Proposed INN: Apremilast<br>Product Name: Apremilast<br>Product Code: AMG407<br>INN or Proposed INN: Apremilast Trade Name: Otezla<br>Product Name: Apremilast 10 mg<br>Product Code: AMG-407<br>INN or Proposed INN ... | Amgen Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes<br>Male: yes | 60 | Phase 3 | France;Greece;Israel;Netherlands;Switzerland | ||
| 8 | ChiCTR2100045463 | 2021-05-0120210501 | 2021-04-1520210415 | Efficacy and safety of Adalimumab in refractory intestinal Behcet’s disease: A single-center, interventional, open-label, single-arm study Efficacy and safety of Adalimumab in refractory intestinal Behcet’s disease: A single-center, interv ... | Efficacy and safety of Adalimumab in refractory intestinal Behcet’s disease: A single-center, interventional, open-label, single-arm study Efficacy and safety of Adalimumab in refractory intestinal Behcet’s disease: A single-center, interv ... | intestinal Beh?et's disease | One-armed intervention group:adalimumab; | The First Affiliated Hospital, College of Medicine, Zhejiang University | NULL | Recruiting | 18 | 70 | Both | One-armed intervention group:30; | Phase 4 | China |
| 9 | ChiCTR2100044593 | 2021-03-1520210315 | 2021-03-2420210324 | Clinical study of endoscopic treatment for Patients with intestinal Behcet's disease having poor response to conventional treatment Clinical study of endoscopic treatment for Patients with intestinal Behcet's disease having poor res ... | Clinical study of endoscopic treatment for Patients with intestinal Behcet's disease having poor response to conventional treatment Clinical study of endoscopic treatment for Patients with intestinal Behcet's disease having poor res ... | intestinal Behcet's disease | Single group:Endoscopic injection of triamcinolone acetonide; | The First Affiliated Hospital of Sun Yat-Sen University | ,NULL | Recruiting | 16 | 70 | Both | Single group:30; | China | |
| 10 | ChiCTR2000037172 | 2021-01-0120210101 | 2020-08-2720200827 | Randomized Double-blind Controlled Study of Shenshi Shengdiqinlian Tufuling Decoction in the Treatment of Mucocutaneous Behcet's Disease Randomized Double-blind Controlled Study of Shenshi Shengdiqinlian Tufuling Decoction in the Treatme ... | Randomized Double-blind Controlled Study of Shenshi Shengdiqinlian Tufuling Decoction in the Treatment of Mucocutaneous Behcet's Disease Randomized Double-blind Controlled Study of Shenshi Shengdiqinlian Tufuling Decoction in the Treatme ... | Behcet's Disease | experimental group:Shen's Qinlian Soil Fuling Granules + Thalidomide Tablets;control group:placebo + Thalidomide Tablets ; experimental group:Shen's Qinlian Soil Fuling Granules + Thalidomide Tablets;control group:placebo + ... | Shanghai Traditional Chinese Medicine Hospital | NULL | Pending | 16 | 70 | Both | experimental group:60;control group:60; | China |
107. 若年性特発性関節炎
臨床試験数 : 447 / 薬物数 : 297 - (DrugBank : 57) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 146
Showing 1 to 10 of 447 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04585711 (ClinicalTrials.gov) | May 202320230500 | 7/10/202020201007 | Pharmacokinetics and Pharmacodynamics of Biologic Drugs in Obese Patients With Arthritis | Pharmacokinetics and Pharmacodynamics of Biologic Drugs in Obese Patients With Arthritis | Juvenile Idiopathic Arthritis;Rheumatoid Arthritis;Obesity | Drug: Etanercept Optimal dosing | Duke University | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Not yet recruiting | 2 Years | 65 Years | All | 30 | Phase 1 | United States |
| 2 | NCT05609630 (ClinicalTrials.gov) | March 15, 202320230315 | 7/11/202220221107 | Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Ac ... | A Multicenter, Randomized Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Upadacitinib With a Tocilizumab Reference Arm in Subjects From 1 Year to Less Than 18 Years Old With Active Systemic Juvenile Idiopathic Arthritis A Multicenter, Randomized Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of U ... | Juvenile Idiopathic Arthritis | Drug: Upadacitinib;Drug: Tocilizumab | AbbVie | NULL | Not yet recruiting | 1 Year | 17 Years | All | 90 | Phase 3 | NULL |
| 3 | EUCTR2022-003024-41-ES (EUCTR) | 25/01/202320230125 | 25/11/202220221125 | Apremilast study in children with active oral ulcers associated with Behçet's Disease or Juvenile Psoriatic Arthritis Apremilast study in children with active oral ulcers associated with Behçet's Disease or Juvenile Ps ... | A Phase 3, Multicenter, Open-label, Long-term Extension Study of Apremilast in Children 2 Years of Age or Older With Oral Ulcers Associated With Behçet’s Disease or 5 Years of Age or Older With Juvenile Psoriatic Arthritis A Phase 3, Multicenter, Open-label, Long-term Extension Study of Apremilast in Children 2 Years of A ... | Subjects with active Behçet's Disease or Juvenile Psoriatic Arthritis <br>MedDRA version: 21.1;Level: LLT;Classification code 10004212;Term: Behcet's disease;System Organ Class: 100000004866 <br>MedDRA version: 20.0;Classification code 10079454;Term: Systemic juvenile idiopathic arthritis;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Subjects with active Behçet's Disease or Juvenile Psoriatic Arthritis <br>MedDRA version: 21.1;Level ... | Trade Name: Otezla<br>Product Name: Apremilast 20 mg<br>Product Code: AMG 407<br>INN or Proposed INN: Apremilast<br>Trade Name: Otezla<br>Product Name: Apremilast 30 mg<br>Product Code: AMG 407<br>INN or Proposed INN: Apremilast<br>Product Name: Apremilast<br>Product Code: AMG 407<br>INN or Proposed INN: Apremilast Trade Name: Otezla<br>Product Name: Apremilast 20 mg<br>Product Code: AMG 407<br>INN or Proposed INN ... | Amgen Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes<br>Male: yes | 48 | Phase 3 | France;Greece;Spain;Turkey;Israel;United Kingdom;Italy;Switzerland | ||
| 4 | NCT05534347 (ClinicalTrials.gov) | September 202220220900 | 6/9/202220220906 | Angiogenic Biomarkers in Juvenile Idiopathic Arthritis | Angiogenic Inflammatory Biomarkers in Juvenile Idiopathic Arthritis | Juvenile Idiopathic Arthritis (JIA) | Biological: Blood sample;Biological: Joint puncture | Assistance Publique - Hôpitaux de Paris | NULL | Not yet recruiting | 16 Years | N/A | All | 300 | France | |
| 5 | JPRN-jRCT2031220187 | 01/08/202220220801 | 07/07/202220220707 | Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS ... | A Two-cohort, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still's Disease (Including Systemic Juvenile Idiopathic Arthritis and Adult Onset Still's Disease) or with MAS in Systemic Lupus Erythematosus - EMERALD A Two-cohort, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerabilit ... | Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, SLE | Emapalumab iv infusion<br>initial dose: 6 mg/kg<br>Subsequent doses: 3 mg/kg | Nakaoku Takahiro | NULL | Recruiting | >= 6month old | <= 80age old | Both | 2 | Phase 2-3 | Belgium;Canada;China;Czechia;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;Japan Belgium;Canada;China;Czechia;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;Uni ... |
| 6 | JPRN-jRCT2031220222 | 01/07/202220220701 | 25/07/202220220725 | Sobi.ANAKIN-303 | A randomized, double-blind, placebo-controlled, multicenter, phase 3 efficacy and safety study of subcutaneous anakinra in Japanese patients with Still's disease (SJIA and AOSD) A randomized, double-blind, placebo-controlled, multicenter, phase 3 efficacy and safety study of su ... | Systemic juvenile idiopathic arthritis(SJIA)., adult-onset Still's disease (AOSD) | - Pediatric and adult patients weighing >_ 50kg:Anakinra 100mg/day - Pediatric and adult patients weighing < 50 kg:should be dosed by body weight with a starting dose of 2mg/kg/day of anakinra (with a maximum of 100mg/day) -Pediatric and adult patients weighing >_ 50kg:Anakinra 100mg/day - Pediatric and adult patients weig ... | Takeshi KUROSAWA | NULL | Recruiting | >= 8month old | Not applicable | Both | 15 | Phase 3 | Japan |
| 7 | NCT05540743 (ClinicalTrials.gov) | July 1, 202220220701 | 12/9/202220220912 | Biologic Therapy in Pediatric JIA Uveitis | The Efficacy of Anti-TNF Alpha Agents in the Treatment of JIA- Associated Uveitis in a Pediatric Cohort The Efficacy of Anti-TNF Alpha Agents in the Treatment of JIA- Associated Uveitis in a Pediatric Coh ... | Juvenile Idiopathic Arthritis Associated Uveitis | Drug: biologic DMARDs | Kasr El Aini Hospital | NULL | Active, not recruiting | 3 Months | 16 Years | All | 250 | Phase 4 | Egypt |
| 8 | EUCTR2011-004915-22-NL (EUCTR) | 17/05/202220220517 | 05/02/202120210205 | A Long-Term, Open-Label, Study for Treatment of JIA | A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITI ... | JUVENILE IDIOPATHIC ARTHRITIS (JIA) <br>MedDRA version: 23.1;Level: PT;Classification code 10059176;Term: Juvenile idiopathic arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] JUVENILE IDIOPATHIC ARTHRITIS (JIA) <br>MedDRA version: 23.1;Level: PT;Classification code 10059176; ... | Trade Name: XELJANZ<br>Product Code: CP-690,550-10<br>INN or Proposed INN: Tofacitinib<br>Product Code: CP-690,550-10<br>INN or Proposed INN: Tofacitinib Trade Name: XELJANZ<br>Product Code: CP-690,550-10<br>INN or Proposed INN: Tofacitinib<br>Product Co ... | Pfizer Inc, 235 East 42nd Street, New York, New York 10017 | NULL | Authorised-recruitment may be ongoing or finished | Female: yes<br>Male: yes | 340 | Phase 2;Phase 3 | United States;Slovakia;Spain;Costa Rica;Ukraine;Turkey;Chile;Israel;Russian Federation;United Kingdom;Italy;Hungary;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Australia;South Africa;Germany;Netherlands;China;Sweden United States;Slovakia;Spain;Costa Rica;Ukraine;Turkey;Chile;Israel;Russian Federation;United Kingdo ... | ||
| 9 | EUCTR2019-002788-88-GR (EUCTR) | 14/04/202220220414 | 01/02/202220220201 | Apremilast Study in Children with Active Juvenile Psoriatic Arthritis | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis (PEAPOD) A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evalua ... | Juvenile psoriatic arthritis <br>MedDRA version: 20.0;Level: LLT;Classification code 10079454;Term: Systemic juvenile idiopathic arthritis;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Juvenile psoriatic arthritis <br>MedDRA version: 20.0;Level: LLT;Classification code 10079454;Term: ... | Trade Name: Otezla<br>Product Name: Apremilast 10 mg<br>Product Code: AMG-407<br>INN or Proposed INN: Apremilast<br>Trade Name: Otezla<br>Product Name: Apremilast 20 mg<br>Product Code: AMG-407<br>INN or Proposed INN: Apremilast<br>Trade Name: Otezla<br>Product Name: Apremilast 30 mg<br>Product Code: AMG-407<br>INN or Proposed INN: Apremilast<br>Product Name: Apremilast<br>Product Code: AMG407<br>INN or Proposed INN: Apremilast Trade Name: Otezla<br>Product Name: Apremilast 10 mg<br>Product Code: AMG-407<br>INN or Proposed INN ... | Amgen Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes<br>Male: yes | 60 | Phase 3 | France;Greece;Poland;Belgium;Austria;Netherlands;Italy | ||
| 10 | EUCTR2017-002018-29-HU (EUCTR) | 04/01/202220220104 | 25/10/202120211025 | Efficacy and Safety Study Of Tofacitinib in Pediatric sJIA Population | EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (sJIA) WITH ACTIVE SYSTEMIC FEATURES IN CHILDREN AND ADOLESCENT SUBJECTS EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENIL ... | Systemic Juvenile Idiopathic Arthritis (sJIA);Therapeutic area: Diseases [C] - Immune System Diseases [C20] Systemic Juvenile Idiopathic Arthritis (sJIA);Therapeutic area: Diseases [C] - Immune System Disease ... | Product Name: Tofacitinib citrate<br>Product Code: CP-690,550-10<br>INN or Proposed INN: tofacitinib<br>Other descriptive name: TOFACITINIB CITRATE<br>Product Name: Tofacitinibe citrate<br>Product Code: CP-690-550-10<br>INN or Proposed INN: tofacitinib<br>Other descriptive name: APD421<br>Product Name: Tofacitinibe citrate<br>Product Code: CP-690-550-10 (DMID D1600180)<br>INN or Proposed INN: tofacitinib<br>Other descriptive name: APD421 Product Name: Tofacitinib citrate<br>Product Code: CP-690,550-10<br>INN or Proposed INN: tofacitinib ... | Pfizer Inc. 235 East 42nd Street, New York, New York 10017 | NULL | Authorised-recruitment may be ongoing or finished | Female: yes<br>Male: yes | 100 | Phase 3 | United States;Slovakia;Spain;Costa Rica;Ukraine;Turkey;Israel;Russian Federation;United Kingdom;Italy;India;Hungary;Mexico;Canada;Argentina;Poland;Belgium;Brazil;South Africa;Netherlands;Germany;China;Sweden United States;Slovakia;Spain;Costa Rica;Ukraine;Turkey;Israel;Russian Federation;United Kingdom;Ital ... |